---
title: "International Generosity Foundation Trust Discloses Investment at Barinthus with 6.7% Stake"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282582951.md"
description: "International Generosity Foundation Trust has disclosed a 6.7% stake in Barinthus Biotherapeutics plc, as filed in Schedule 13D on April 13, 2026. The trust aims to support its charitable work through this investment, with no current plans for governance changes or board seats. It may buy or sell shares over time to fund grants, focusing on preserving and growing capital for ongoing charitable distributions. The trust is a U.S.-based 501(c) charitable organization funded through donations and donor-advised funds."
datetime: "2026-04-13T19:36:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282582951.md)
  - [en](https://longbridge.com/en/news/282582951.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282582951.md)
---

# International Generosity Foundation Trust Discloses Investment at Barinthus with 6.7% Stake

International Generosity Foundation Trust disclosed a 6.7% stake in Barinthus Biotherapeutics plc. The Schedule 13D was filed on Apr. 13, 2026. The move highlights a charitable trust building a meaningful position without seeking governance changes.

**Investor Intent**

International Generosity Foundation Trust holds the shares for investment and to support its charitable work. It states it "acquired the securities for investment purposes and in connection with its charitable activities."

The trust may buy more or sell shares over time, including to fund grants, and it has no current plans for board seats, mergers, or other corporate actions. As it notes, it "may, from time to time, sell or otherwise dispose of some or all of the securities, including to support its charitable purposes."

**Investor's Background**

International Generosity Foundation Trust is a U.S.-based 501(c) charitable trust managed by a trustee. It is generally funded through donations and donor-advised funds and invests its assets to support giving. The trust typically focuses on preserving and growing capital to sustain ongoing charitable distributions.

Original SEC Filing: Barinthus Biotherapeutics plc. \[ BRNS \] - SCHEDULE 13D - Apr. 13, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BRNS.US](https://longbridge.com/en/quote/BRNS.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)
- [Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition](https://longbridge.com/en/news/286608288.md)